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Abstract
Liquid biopsies represent an innovative methodology for cancer diagnostics and disease 
monitoring. The analysis of circulating cell-free nucleic acids (CFNA) and circulating 
tumour cells (CTC) are rapidly being adopted for quantitative and qualitative charac-
terisation of the tumour genome and as a mode of non-invasive therapeutic monitor-
ing. Circulating cell-free DNA (cfDNA) and CTC are representative of the underlying 
mutational profile of a cancer whereas the evaluation of extracellular RNA (exRNA) can 
be utilised as a prognostic biomarker thus providing critical biological information both 
at the time of diagnosis and during disease evolution. In this chapter, we will review the 
emerging utility of CFNA and CTC as biomarkers of prognosis and for both mutational 
characterisation and monitoring disease progression, and how these have the potential 
to provide additional information as an adjunct to bone marrow biopsies and conven-
tional disease markers in multiple myeloma (MM). Emerging data suggest that liquid 
biopsies might offer a potentially simple, non-invasive, repeatable analysis that can aid 
in diagnosis, prognostication and therapeutic decision making in MM, with particular 
applicability in subsets of patients where conventional markers of disease burden may 
be less informative.
Keywords: cell-free nucleic acids, multiple myeloma, liquid biopsy, circulating tumour 
cells, non-invasive, diagnostics, disease burden
1. Introduction
1.1. Multiple myeloma
Multiple Myeloma (MM) is a multi-focal genetically heterogeneous clonal plasma cell (PC) 
malignancy that at diagnosis is present at multiple intra-medullary sites within the bone mar-
row (BM, Figure 1). It is the second most common haematological malignancy after lym-
phomas [1]. MM is preceded by a usually unrecognised asymptomatic clonal PC disorder 
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exclusively confined to the BM called monoclonal gammopathy of undetermined significance 
(MGUS) [2, 3]. During disease progression the PCs evolve the capacity to grow independently 
of the BM milieu and thus proliferate outside of the BM, manifesting as extramedullary (EM) 
MM and/or plasma cell leukaemia (PCL), with published observations showing that PCL rep-
resents a more genetically abnormal sub-clone that evolves from the original intra-medullary 
PC population [4]. The incidence of EM soft-tissue plasmacytomas in newly diagnosed (ND) 
patients ranges from 7 to 18% with an incidence of almost 20% at the time of relapse [5, 6]. The 
diagnosis and monitoring of MM relies on sequential BM biopsies and the quantitation of bio-
markers of disease burden in the blood and/or urine - clonal immunoglobulin (paraprotein, 
PP) and/or isotype restricted free-light chains (Serum Free light chains, SFLC or Bence Jones 
Proteinuria) and in 15–20% of patients the MM cells secrete only SFLC, so called light chain 
MM [7]. Notably, the routine biomarkers of tumour burden are not informative in subsets 
of patients with oligo-secretory (OS)-MM or non-secretory (NS)-MM, which are subsets of 
MM that have low or no measureable levels of PP (<10 g/L) and/or SFLC (<100 mg/L), respec-
tively, and constitute about 10% of MM patients at diagnosis (Australian National Myeloma 
and Related Diseases Registry, [8]). Moreover, patients with secretory MM at the time of 
initial diagnosis can transform to NS-MM or OS-MM at the time of relapse and patients 
with advanced disease are significantly more likely to have OS-MM disease compared to 
ND patients [8]. These low or immeasurable levels of PP prevent a patient’s disease from 
Figure 1. Multiple myeloma (MM) is a multi-focal malignancy manifesting at several sites black within the BM at 
diagnosis and in EM tissues in more advanced stages. (A) A PET image of a patient with MM is shown here, demonstrating 
disease foci at multiple sites (shown in the circles) with the potential that the tumour genome at these individual sites 
may demonstrate clonal heterogeneity. (B) Representation of the potential changes in clonal and sub-clonal fractions 
(represented in the different sized circles) are shown with the increasing spatial heterogeneity thought to be present during 
disease progression. Primary translocations of the IgH gene locus and chromosomal aneuploidies occur during MGUS 
and chromosomal abnormalities along with primary and secondary driver mutations emerge during MM progression.
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being monitored using traditional blood and urine tests and as such OS-MM and NS-MM 
patients are typically ineligible to participate in clinical trials of newer anti-MM therapeutics. 
Conventionally, therefore, treatment response in these patients is determined via sequential 
BM biopsies, where available, and whole-body PET/CT or MRI represent the only accepted 
non-invasive modality for following response in NS-MM. Therefore, despite well-established 
diagnostic and monitoring modalities, there remains a critical need to address specific subsets 
of patients where these conventional markers are inadequate.
The treatment of MM has witnessed significant progress with the introduction of proteasome 
inhibitors (PI) and immunomodulatory agents (IMID), however, the disease remains incur-
able. MM cells acquire resistance to systemic therapies through the accumulation of mutations 
that are often not present during the initial stages of the disease [9] with this genetic evolution 
providing the more resistant clones with a growth and survival advantage (Figure 1, [10]). 
Mutational characterisation of MM utilising whole genome sequencing (WGS) or whole exome 
sequencing (WES) of single-site BM biopsies predominantly of ND patients have indicated that 
the MM mutational spectrum is both complex and heterogeneous with recurring mutations 
in KRAS, NRAS, TP53, BRAF, IRF4, MAX, ATM, ATR, CCND1, CYLD, DIS3, BRAF, FGFR3, 
RB1, HIST1H1E, EGR1, TRAG3, FAM46C and LTB [11–14]. The MM mutational landscape is 
dominated by RAS-MAPK pathway mutations (45–50%) and while these mutations can be 
targeted therapeutically, the biological implication of the presence of these mutations remains 
controversial. Chng WJ and co-authors observed that the presence of KRAS mutations, but 
not NRAS mutations, was associated with inferior overall survival (OS) and a more aggressive 
disease phenotype [15]. However, it has been recently demonstrated that NRAS mutations 
may confer reduced sensitivity to bortezomib but not dexamethasone, while the presence of 
KRAS mutations does not appear to correlate with drug sensitivity [16]. Conversely, more 
recent studies have concluded that harbouring RAS mutations has no significant impact on 
disease outcome [13, 14]. In contrast, available data suggests that the presence of mutations 
involving the DNA damage response genes (TP53, ATM and ATR) is associated with a nega-
tive impact on survival [14]. Recently, mutational analysis of PCs from 33 MGUS patients indi-
cated that while the number of somatic mutations was significantly lower when compared to 
MM the spectrum of mutations mirrored that of MM with KRAS, NRAS, DIS3, HIST1H1E, 
EGR1 and LTB mutations being observed [17]. Importantly, mutations in the DNA damage 
response genes were not found, indicating that these are secondary drivers accounting for dis-
ease progression and drug resistance. Notably, one patient harboured both KRAS and NRAS 
mutations highlighting that diversification and heterogeneity in this pathway may exist before 
the development of symptomatic MM [17]. To date the mutational characterisation of MM 
has utilised single-site BM biopsies, however, it is now increasingly recognised that such an 
approach may fail to capture the spatial and temporal genetic heterogeneity of this multi-focal 
disease, self-evidently with EM MM, but also, based on emerging data, in patients with ‘typical 
MM’ manifesting intra-clonal heterogeneity [11, 18–20]. Moreover, both spatial and temporal 
genetic heterogeneity are now recognised as adding to the genetic complexity of the disease 
as it evolves [21]. This is exemplified by recent observations from comparisons of BM and tar-
geted biopsies of EM disease that sub-clones absent from the BM may be present at EM sites 
and critically, that these disease foci may respond differentially to treatment (Figure 2, [9, 22]). 
Therefore, despite the pivotal BM-based studies that currently inform our understanding of 
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the mutational  spectrum in MM, the evident shortcomings of these approaches necessitates 
the adoption of newer and more novel strategies to enable the more comprehensive genomic 
characterisation of the disease.
1.2. Liquid biopsy
The utilisation of liquid biopsies continues to generate significant attention as it represents a 
platform that has the potential to provide rapidly evaluable and non-invasive, genomic char-
acterisation of a patient’s cancer. In simple terms, liquid biopsy refers to analyses that utilise 
blood or bodily fluids that contain circulating tumour cells (CTC) and/or fragments of nucleic 
acids or proteins that are derived from primary and/or secondary tumour sites. This material 
can then be interrogated to provide comprehensive information about the tumour genome 
and other biological characteristics of the disease. Moreover, liquid biopsies can be used to 
monitor the effects of therapy and may provide early evidence of recurrence or relapse of 
disease enabling early and informed changes in disease treatment. In this section, the two 
most widely studied types of liquid biopsy sources, CTC and cell-free nucleic acids (CFNA), 
will be discussed.
Figure 2. Different sites in a MM patient may respond differentially to treatment. PET image of a MM patient receiving 
thalidomide therapy taken 2 months apart showing regression of disease at one site (pelvis), while tumour growth is 
observed at another site (humerus).
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1.2.1. Circulating tumour cells (CTC)
CTC are intact tumour cells that disengage from tumour sites thus entering the circulation 
and are a recognised feature of metastatic cancers [23–25]. Historically, CTC were considered 
to be present only in a sub-set of ND, untreated or end-stage MM patients. Now with the 
advent of highly sensitive next-generation (NG) flow cytometry techniques the detection of 
CTC in pre-malignant MGUS and at different stages in MM has become feasible [26–28] and 
CTC can be detected in the peripheral blood of a substantial proportion of MM patients evalu-
ated in this fashion [29, 30]. Importantly, the numbers of CTC in the peripheral blood in MM 
patients with active disease is known to be significantly higher than in patients with inactive 
disease, with higher numbers of CTC being a risk factor for progression to symptomatic MM 
for patients with either MGUS or smouldering MM (SMM) [29–33]. The number of CTC in 
ND and RR patients is also known to be an independent prognostic factor for survival [34–37]. 
Finally, the absolute numbers of CTC was found in one study to be a better predictor of dis-
ease activity than SFLC ratios [30].
1.2.2. Circulating cell-free nucleic acids (CFNA)
CFNA, refers to cfDNA and extracellular RNA (exRNA - includes mRNA and miRNA), and are 
being widely assessed in an ongoing fashion for their potential utility as blood biomarkers for 
cancer diagnostics. CFNA are derived predominantly through necrosis, spontaneous or che-
motherapy induced apoptosis and active cellular release [38, 39]. Given that CFNA is also pres-
ent at higher levels in certain physiological conditions and clinical scenarios (reviewed in [40]), 
it is critical to determine if the nucleic acids released are tumour-specific in cancer patients. In 
this section the different types of CFNA and their potential clinical utility will be discussed.
1.2.3. Cell-free DNA
The presence of CFNA in body fluids was first described by Mandel and Metais in 1948 [41]. 
One of the earliest observations in relation to cfDNA was that patients with malignant disease 
had higher levels of cfDNA in their serum than normal individuals, and that patients with per-
sistently high levels of cfDNA demonstrated a lack of treatment response [42–44]. Mutated RAS 
fragments and microsatellite alterations in cfDNA were later observed in cancer patients and 
critically these alterations were not detected in paired tissue biopsies, highlighting the concept, 
very early-on, that isolated tissue biopsies may not represent the optimal material for defining 
the tumour genome [45, 46]. The development and utilisation of NGS technologies, WGS and/
or WES of cfDNA containing tumour-derived DNA has identified mutations, tumour-derived 
chromosomal aberrations and gene rearrangements associated with acquired resistance to 
therapy without the need to perform sequential tumour biopsies [47–51]. Furthermore, it is 
evident that secondary mutations are more readily detectable in the plasma than via re-biopsy 
of primary tumours validating the utility of plasma-based analysis for the characterisation 
of potentially targetable oncogenes and the identification of resistance-associated mutations 
that are acquired during disease progression, thus informing therapeutic changes [48, 52, 53]. 
Available evidence would also suggest that cfDNA may be more representative of the entire 
tumour genome than the information derived from single BM or nodal/tumour biopsies, as 
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emerging evidence supports the notion that a range of haematologic malignancies including 
MM are likely to harbour significant sub-clonal and spatial genetic heterogeneity. In MM, lev-
els of cfDNA are significantly higher than in both normal volunteers and non-MM cancers [54, 
55] and the potential utility of cfDNA in MM will be discussed below.
1.2.4. Extracellular RNA (mRNA and miRNA)
The presence of extracellular RNA (exRNA) in plasma/serum was also described some 
decades ago [41, 56, 57] with significantly higher levels in cancer patients compared to healthy 
individuals [58]. Additionally, tumour burden was shown to correlated with the level of cir-
culating mRNA [59]. The exRNA released into the circulation is surprisingly stable owing to 
its protection from RNAse-mediated degradation through packaging into exosomes, which 
are shed into the blood stream [60–64]. Biomarker studies measuring cancer-specific circulat-
ing mRNA have identified higher level of mRNA and correlation with disease status in a 
number of malignancies including nasopharyngeal carcinoma [65], prostate [66, 67], gastroin-
testinal [68–72], breast [73–76], hepatocellular carcinoma [77], lung [78, 79], cervical [80], lym-
phoma [81] and thyroid [82]. These findings highlight the potential utility of exRNA in cancer 
diagnostics, and while promising, it will be critical to assess exRNA in larger and annotated 
sample sets to establish specific circulating mRNAs as reliable non-invasive biomarkers.
Similarly, extracellular miRNA are found in virtually all fluid compartments of the body 
including blood where they can circulate bound to proteins, high-density lipoproteins or 
apoptotic bodies, or within exosomes, thus providing stability against RNases (reviewed 
in [83]). The levels of circulating miRNA have been described in a number of cancers with 
one of the earliest reports being in diffuse large B-cell lymphoma (DLBCL) demonstrating a 
correlation between the level of specific miRNAs and prognosis [84]. Subsequently, several 
publications of circulating miRNA in malignancy have demonstrated increased miRNA in 
cancer patients when compared to healthy individuals and a decrease in levels following 
tumour debulking surgery (reviewed in [85–87]). Circulating miRNA expression profiles are 
also known to have signatures correlative to disease stage, diagnosis and relapse [88–91]. The 
origin of circulating RNA subtypes is, however, not as well understood as for cfDNA, as these 
can potentially be sourced from tumour cells, the supporting micro-environment or immune 
cells [92]. While mRNA has not been assessed in MM, there are a number of studies of miRNA 
and the prognostic utility of these will be discussed in the next section.
2. Biological and clinical implications of liquid biopsy analysis in MM
Liquid biopsy is gaining momentum in MM due to the inherent nature of the disease and the 
obvious limitations associated with BM biopsy. A summary of the potential utility of CTC and 
CFNA evaluation are presented in this section (Figure 3).
2.1. Determining the tumour genome composition
Given the clonal genomic heterogeneity that exists within MM, particularly with disease 
progression, it is theoretically necessary to perform repeated BM biopsies to track tumour 
Hematology - Latest Research and Clinical Advances78
genomic evolution within any particular patient. Such an approach, however, remains an 
unattractive proposition as BM biopsies are invasive, not without complications, subject to 
sampling error and cannot capture the increasing spatial heterogeneity present with disease 
evolution. Therefore, the capacity to perform sequential mutational characterisation using 
a more ‘holistic’ and non-invasive approach would be a highly desirable alternative option. 
Both CTC and CFNA have been explored for this purpose in MM, however, the field is rela-
tively unestablished with only a small number of publications addressing this concept. One 
of the earliest reports by Zandecki et al. evaluated CTC and matched BM-MM cells and dem-
onstrated that chromosomal abnormalities were consistent between these two compartments 
[93]. The recent development of both NG flow cytometry and contemporary sequencing tech-
nologies has enabled the analysis of CTC at the single-cell level [27] but to date only small 
numbers of patients have been evaluated using this approach. Analysis of 9 patients with 
single cell WGS revealed that all BM-defined mutations were similarly present in CTC [27]. 
Further analysis was done on CTC in two patients with low disease burden (one with treated 
MM and one with MGUS). The CTC of the MM patient harboured readily detectable somatic 
mutations in BRAF, TP53 and IRF4, with reappearance of the mutations when the patient 
relapsed, indicating that the treatment had not eradicated these particular sub-clones. CTC 
analysis of the patient with MGUS revealed the presence of a NRAS mutation, also present 
in the BM. The concordance with BM genetic composition was also confirmed by Mishima 
et al. utilising NGS when analysing 8 paired CTC and BM aspirates [28]. Clonal, defined 
as a > 0.90 mutant allele fraction (MAF), mutations were present in >99% of CTC and BM, 
while subclonal shared mutations (defined as >0.05 MAF) were concordant in >80%, with 16% 
of subclones (<0.05 MAF) discordant between the two compartments consistent with spatial 
Figure 3. Currently in MM, BM-derived tumour cells are utilised for mutational characterisation, biomarker identification 
and to define disease burden. Peripheral blood can be utilised to obtain both CTC and CFNA. DNA and RNA can be 
derived from both sources and as both CTC and CFNA are derived from multiple tumour sites they theoretically will 
provide a more comprehensive profile of the disease in comparison to a single-site BM biopsy.
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heterogeneity [28]. Similarly, copy number alternations (CNA) were assessed and found to 
be 92% concordant. Likewise, RNA-seq at the single cell level also accurately predicted the 
recognised non-random chromosomal translocations that manifest in MM responsible for 
overexpression of key MM-associated oncogenes [27]. Overall, for both somatic mutations 
and CNA, CTC appear to harbour more variances indicating that they are likely sourced from 
multiple tumour sites and the manifestations of spatial heterogeneity may thus be more accu-
rately captured by this type of analysis.
The evaluation of cfDNA for mutational characterisation and monitoring of disease burden in 
MM has also recently been described [54, 55, 94, 95]. Importantly, and for the first time, spa-
tial and clonal heterogeneity on a large scale in MM was confirmed by our study evaluating 
paired BM-derived CD138 selected MM cells and cfDNA utilising a highly sensitive targeted 
sequencing platform consisting of a panel of 96 cancer-associated mutations including muta-
tions of KRAS, NRAS, BRAF and TP53. This demonstrated that 21% of MM patients had muta-
tions detectable only in the plasma and that the prevalence of spatial heterogeneity increased 
with disease evolution [55]. Numerous signalling pathways are known to be mutated in MM 
[13, 14], with previous BM WES studies demonstrating that activating mutations of the RAS-
MAPK pathway were present in approximately 50% of patients. In contrast, our study dem-
onstrated RAS-MAPK activating mutations in 69% of cases and the co-existence of multiple 
mutated sub-clones in a significant proportion, with >3 activating mutations in 23% of patients 
(range, 3–17 mutations per patient) representing a hitherto unrecognised mutational conver-
gence on the RAS-MAPK pathway. This had remained largely undiscovered in single-site BM 
WES studies owing presumably to the relative insensitivity of the methodologies used and 
the presence of clonal heterogeneity at sites distant to the BM biopsy site. While it is likely, 
with high-sensitivity approaches, that there will be a MAF threshold for minor BM sub-clones 
that enables them to be reproducibly detected in the plasma, this will not be relevant with less 
sensitive strategies like WES and targeted amplicon sequencing that cannot detect smaller 
sub-clonal mutations, thus explaining, and consistent with, the 96% concordance between 
BM and PL demonstrated using NGS technologies [54]. Interestingly, mutations in PIK3CA, 
which have only rarely been described in MM, were found in a recent study to be present, but 
only in the plasma, indicating that these could be a feature of EM disease [54]. However, 
confirmatory studies with larger cohorts of patients and more comprehensive and targeted 
panels of MM-associated mutations are required to validate these observations. Theoretically, 
therefore, plasma cfDNA analysis of MM patients, particularly in the case of EM-MM, would 
not only provide information on the underlying biology of this disease, but could also furnish 
information on response to therapy through quantitative sequential tracking of plasma-only 
mutations. Moreover, RNA-seq of plasma cfRNA derived from MM patients is also theoreti-
cally possible to provide information on single nucleotide polymorphisms (SNP), although 
this has not yet been described in the published literature. So, while in the short-term it is 
unlikely that plasma cfDNA evaluation will replace BM biopsy, as the latter remains neces-
sary in MM for diagnostic purposes, we believe cfDNA analysis as an adjunct to BM biopsy 
for comprehensive mutational characterisation is likely to become a reality in the near future.
To date, the analysis of CTC or cfDNA with paired BM has largely been performed only 
at single time-points and has not been comprehensively utilised for longitudinal assess-
ment using sequential specimens that would be critical to identify the evolution of the 
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clonal architecture of the disease during therapy. The prognostic significance of mutational 
profiling in MM also remains largely unknown, with only a few genes thought to have 
prognostic significance. Furthermore, it should be recognised that the prognostic impact of 
certain mutations has been based on studies profiling material sourced from BM aspirates 
and therefore may not have been representative of the entire tumour genome. This shortfall 
could be potentially overcome using CTC and/or ctDNA as an adjunct to BM biopsy for 
mutational analysis and consequently, for prognostic profiling.
2.2. Biomarkers
The establishment of single-cell RNA-seq methodology in CTC from MM patients [27] pres-
ents an important opportunity for the identification of biomarkers that may define differing 
sub-sets and stages of the disease. Theoretically, this may represent a technically feasible and 
hence more reliable strategy than evaluation of exRNA as the RNA would be derived from 
tumour cells that should overcome some of the stability issues that may be associated with 
exRNA. Furthermore, CTC-derived RNA should address the issue of spatial heterogeneity 
and hence provide a more inclusive RNA-signature during disease evolution, as compared to 
present data based on single-site BM biopsies. To date, the potential of exRNA for differen-
tiating the continuum of plasma cell dyscrasias ranging from MGUS to intra-medullary, EM 
MM and PCL has been explored in MM, but mainly through the analysis of miRNA and not 
mRNA (reviewed in [83]). Available evidence would suggest that MM cells contain differing 
populations of miRNA species at defined disease stages [96–100], therefore an approach iden-
tifying miRNA biomarkers non-invasively utilising exRNA would represent a readily acces-
sible and novel approach. However, while circulating miRNA biomarker studies, including 
patients from different disease stages, have defined relative differences in both the expression 
of specific miRNAs and the absolute levels of circulating miRNAs as potential biomarkers 
[101–109] there is widespread discordance between the published studies with respect to the 
specific miRNAs identified [83]. For example, Yoshizawa et al. found significant downreg-
ulation of miR-92a in patients with symptomatic MM when compared to normal subjects, 
conversely, Besse et al. when comparing serum miRNA profiles between healthy, ND and 
EM patients, demonstrated that miR-130a expression was significantly decreased in the EM 
patients, hence a potential biomarker for EM disease, but no correlation with patient outcome 
was evident [101]. Jones et al., identified that a combination of miR-1246 and miR-1308 could 
distinguish MGUS from MM patients [106], whereas miR-25 was shown to correlate with con-
ventional serum markers of MM at both diagnosis and at complete response (CR) post autolo-
gous stem-cell transplantation (ASCT) [103]. Some of the studies also identified a prognostic 
correlation with the actual levels of circulating miRNA. Rocci et al. demonstrated that miR-16 
and 25 were significantly associated with OS in ND MM [102]. Qu et al. identified miR-483-5p 
as a potential predictor of MM survival [110]. Hao et al. showed that lower expression of miR-
19a predicted poor OS [107], while Kubiczkova et al. concluded that a combination of miR-34a 
and let-7e can distinguish MM patients from normal individuals, and that patients with lower 
levels of miR-744 and let-7e had shorter OS [105]. In parallel with these studies, an evaluation 
of exosome-derived miRNA demonstrated that both let-7b and miR-18a were significantly 
associated with progression-free survival (PFS) and OS [111]. Unlike CTC, one of the sig-
nificant shortcoming of assessing circulating miRNA levels is that expression levels might be 
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impacted upon by both the biological characteristics of the disease and the tumour burden, 
thereby presenting significant challenges when it comes to identifying correlations with prog-
nosis. Moreover, the discrepancy between these studies highlights the lack of concordance 
between the analytical methodologies, study populations and treatment regimens employed. 
A recent publication that provided a systematic review and meta-analysis of 7 circulating 
miRNA studies in MM established that utilising a combination of miRNAs rather than single 
miRNAs would be more effective in the diagnosis and prognostic classification of MM [112].
2.3. Therapeutic monitoring
Longitudinal and dynamic monitoring of CTC and CFNA could provide an avenue for 
detecting loss of response in patients before the emergence of clinical relapse. This could be 
particularly useful in patients with minimal residual disease (MRD) or when conventional 
markers are inadequate. MM treatment has witnessed significant progress with the utilisa-
tion of novel therapies including PI and IMID with approximately 75% of patients achieving 
a near-complete response (CR) or CR with front-line therapy. In this context the attribution of 
MRD negativity has emerged as a paradigm that may be critical in informing treatment deci-
sions. While MM invariably relapses, MRD-negative patients consistently demonstrate more 
prolonged PFS and may represent a group where therapeutic de-escalation or modification 
can be safely considered [113, 114]. Consequently, the necessity for highly sensitive assays to 
detect MRD is critical and this has led to the development and increasing adoption of NGS 
MRD approaches [115–119]. Currently, MRD status is determined via single site BM biopsy, 
which clearly has its limitations. Given that the numbers of CTC in the peripheral blood in 
MM patients with active disease is known to be significantly higher than in patients with inac-
tive disease and the developments in the detection of CTC in MM, the possibility of assess-
ing the overall numbers/presence of CTC in patients during therapy for MRD assessment 
is imminent [29–33]. Recently, CTCs were monitored to predict response to in MM patients 
treated within an open-label, randomised, multicenter phase III clinical trial MM5 of newly 
diagnosed MM patients with the authors concluding that CTC detection in conjunction with 
BM for MRD detection [120]. Likewise, cfDNA has been used for dynamic monitoring fol-
lowing surgery/radiotherapy for the detection of residual disease in a number of solid can-
cers, with persistently high or increasing levels of cfDNA detectable mutations post-surgery/
radiotherapy associated with a lack of treatment response and a much greater risk of relapse 
[42], while patients with undetectable levels of somatic mutations in cfDNA have demon-
strated fewer or no recurrences [121]. The monitoring of MRD using cfDNA in diffuse large-
cell B Lymphoma has also demonstrated that the persistence of cfDNA mutations identifies 
patients at risk of recurrence before the emergence of clinical relapse [122]. However, any 
correlation between the presence or re-emergence of cfDNA detectable mutations and disease 
progression has not yet been assessed in MM.
Currently, only three studies in MM have utilised liquid biopsy in comparison with con-
ventional markers of disease burden in sequential plasma samples, of which only one study 
has compared CTC and ctDNA for therapeutic monitoring. All three studies utilised differ-
ent approaches. Oberle and colleagues assessed clonotypic V(D)J rearrangement in CTC and 
cfDNA in a cohort of 27 MM patients. Overall, an association between both the presence 
of cfDNA and CTC V(D)J detectable rearrangements with response was demonstrated [94]. 
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Notably, the study detected V(D)J rearrangement in cfDNA in all patients assessed while rear-
rangements in CTC were only detectable in 70% of patients, indicating that cfDNA, derived 
from CTC, BM and EM tissue, may represent a better medium for disease evaluation than CTC 
alone. Long-term monitoring of recurrently occurring mutations in sequential serum samples 
from 11 patients over a period of 7 years has also been performed in MM [95]. While the 
majority of patients assessed demonstrated a correlation between PP and the quantifiable lev-
els of specific mutations in sequential plasma samples, there were clearly some patients where 
analysis of cfDNA was able to identify impending relapse prior to the emergence of clinical 
relapse, showing the potentially higher sensitivity of cfDNA analysis for disease monitoring. 
However, a major limitation of sequentially monitoring an initially identified mutant clone is 
the possibility a sub-clonal mutations not detectable at diagnosis evolving during relapse or 
being present at an undetectable level initially and subsequently predominating due to selec-
tion pressure. Indeed, this appeared to be evident in one of the patients studied, where the 
initial detection of a BRAF V600E mutation was not maintained despite the continued sero-
logically persisting disease [95]. The evolution of the tumour genome during therapy was also 
clearly demonstrated in our study, in which 7 patients were monitored sequentially [55]. One 
patient in particular demonstrated the potential complexities presented by genomic disease 
evolution. Initially the patient manifested both TP53 R273H and NRAS G13R mutated clones 
that were responsive to therapy with lenalidomide and dexamethasone (Rd). Subsequently a 
rapid increase in SFLC consistent with light-chain escape was coincident with the emergence 
of two new KRAS clones, KRAS G12A and KRAS G12 V. The clonal fraction of both KRAS 
clones reduced with a switch to Ixazomib-cyclophosphamide-dexamethasone (ICd) therapy 
coinciding with a serological response. However, the NRAS G13R clone that was responsive 
to Rd. progressed on ICd in contrast to the TP53 R273H clone that continued to respond, 
Figure 4. Line graph represents the clonal fraction of 4 mutant clones (left Y-axis) and lambda LC (right Y-axis) in 
sequential PL of relapsed patients collected at months 1, 13 and 24 during therapy. Patient relapsed on revlimid and 
dexamethasone with increase in levels of two mutant clones KRAS G12 V and KRAS G12A at month 13 coinciding with 
lambda LC, however, TP53 R273H and NRAS G13R were found to decrease. A switch to Ixazomib, cyclophosphamide 
and dexamethasone (cd) at month 13 decreased levels of KRAS G12A and KRAS G12 V with increasing levels of NRAS 
G13R suggesting differential response of mutant clones to treatment. Image reproduced from [55].
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highlighting the differential responses of the 4 mutant clones to two different lines of therapy 
(Figure 4). These observations signify that comprehensive mutational analysis in sequential 
plasma is critical to define therapeutic response in a timely manner. Plasma ctDNA analysis 
may also represent a novel and informative strategy for disease monitoring in OS-MM and 
NS-MM patients as demonstrated in our recent publication [55]. Sequential plasma ctDNA 
analysis in a ND NS-MM patient over a period of 19 months showed that relapsed disease 
was associated with the reappearance of mutant KRAS G12 V and KRAS G12D clones that 
had been present at diagnosis in the BM and the emergence of two new clones, NRAS G13D 
and NRAS Q61K, with the former showing refractoriness to both Thalidomide – dexametha-
sone, cyclophosphamide, etoposide and cisplatin (T-DCEP) and re-treatment with bortezo-
mib (velcade) – cyclophosphamide – dexamethasone (VCD) and persisting until the patient 
died shortly thereafter from progressive disease (Figure 5). Interestingly the BM biopsy at 
month 19 showed apparent reduction in disease burden coincident with reintroduction of 
VCD but droplet digital PCR (ddPCR) of plasma ctDNA showed an increasing clonal frac-
tion of the NRAS G13D clone consistent with VCD-refractory disease distant to the site of 
BM biopsy. This first-time observation indicates that ctDNA represents a readily accessible 
non-invasive biomarker of disease burden that may be superior to BM biopsy for monitor-
ing treatment response in NS-MM. Overall, all three studies demonstrated the potential for 
ctDNA to be used in monitoring MM patients. Clearly, there were limitations due to small 
sample sizes, lack of homogenous patient treatment and the critical need to be more com-
prehensive in mutational identification to address tumour genome evolution. Future studies 
should therefore incorporate sequential cfDNA assessment adopting NGS-based approaches, 
Figure 5. Line graph represents the clonal fraction of mutant clones by ddPCR in a non-secretory patient, patient 
#2. PL was collected at 1, 3, 13, 17 and 19 months post- diagnosis. The proportion of BM MM cells is shown with an 
increasing clonal fraction of 4 clones coinciding with BM relapse at month 13, only 9 months post-autologous stem cell 
transplantations (ASCT). At month 19 a BM response to VCD was evident but with an increasing abundance of the NRAS 
G13D clone. The patient succumbed to refractory progressive disease shortly afterwards. Image reproduced from [55].
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at diagnosis and subsequent relapses, to quantify previously detected and emergent clones, 
in larger annotated sample sets, thus enabling the comprehensive tracking of mutations and 
assessment of disease burden with correlation to conventional serum biomarkers.
3. Methodologies and challenges
An increasing number of publications have proven the utility of liquid biopsy for cancer 
screening, diagnosis and disease monitoring. However, for this paradigm to be more widely 
incorporated into the clinical setting a standardised approach for both the pre-analytical pro-
cessing and the analytical platforms utilised is necessary. Identification and isolation of MM 
CTC has been established through the utilisation of ultra-sensitive NGS multicolour flow 
cytometry techniques [26–28]. Lohr et al. devised a combination methodology that allowed 
for isolation of CTC using the standard markers (CD138+ CD38+ CD56 variable, CD45 low) 
and serial dilutions to single cells through fluorescence microscopy to improve the detection 
of CTC [27]. Currently, these are the only described methodologies for isolation of CTC and 
more studies are required to standardise the methodologies described.
CFNA analysis relies on the standardisation of collection, processing and optimal storage of 
cfDNA and exRNA, which can now be streamlined with commercially available specialised 
collection tubes that can stabilise blood at room temperature and preserve the white blood 
cells to avoid rupture and therefore contamination with cellular DNA in the plasma (Streck, 
PAXgene, Roche, NORGEN BIOTEK, etc.). Isolation of genomic DNA or RNA from both CTC 
and CFNA, to a large extent, has also been simplified through the use of commercially avail-
able specific isolation kits, although the performance of each of these kits in comparison to 
other conventional methods is controversial [123]. The choice of the NGS methodologies to 
address specific questions is however, more complicated and is confounded by the type of 
nucleic acid being analysed, assay sensitivity and specificity and the heterogeneous content 
of tumour-derived nucleic acids. A substantial technical challenge to overcome in optimis-
ing cfDNA analysis is the level of sensitivity of the various NGS methodologies, as cfDNA 
may contain low-frequency mutant alleles that might not be readily detectable in WES and 
targeted amplicon sequencing, which have a sensitivity between 1 and 5%. This is being 
addressed with the utilisation of unique molecular indices that provide further resolution 
[48, 124] and such approaches are currently offered by a number of commercial companies 
(Rubicon genomics, QIAGEN, Agilent).
Analysis of exRNA is more complicated as a technology-of-choice needs to be determined for 
large-scale identification of potential biomarkers. Additionally, the validation and diagnos-
tic implication of circulating RNA sub-types currently relies on ‘internal controls’ which are 
often not suited for this type of analysis. This could be addressed using absolute quantifica-
tion methods, a plausible approach utilising ddPCR, which provides a more robust approach 
by quantitating targets per unit in serum or plasma, as done in cfDNA studies.
For CFNA and CTC, unfortunately, to date, few of the described methodologies are as yet val-
idated or standardised, complicating generalisability and inter-study comparisons. Overall, 
the field would benefit from establishment of certain guidelines for each aspect of sample 
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analysis to allow for comparison of studies of similar kind. These limitations not withstand-
ing, the analysis of ctDNA has gained significant momentum is the past couple of years, with 
numerous commercial companies offering ‘liquid biopsy’ testing. Such analysis is now fre-
quently integrated into clinical trials and plasma DNA EGFR mutation testing for non-small 
cell lung cancer has recently been approved by the FDA [125–127]. Further commercialisation 
of these ‘liquid biopsies’ as diagnostics is rapidly evolving, but currently is largely limited to 
informing treatment choices in late stage cancers.
4. Conclusions
Liquid biopsy analysis can provide a dynamic and comprehensive picture of the genomic 
landscape in MM. Specifically, serial analysis can provide a non-invasive approach to monitor 
tumour burden and genomic evolution that also incorporates characterisation of the spatial 
and temporal genomic heterogeneity, which predominates over time, in this multi-focal dis-
ease. Accumulating published evidence and imminent developments in the field indicate that 
this type of analysis will provide critical information for precision medicine and likely trans-
form the management of more problematic sub-groups of MM including NS, OS patients and 
those with EM disease. In the future, instead of utilising extensive imaging and invasive and 
potentially misrepresentative BM biopsies, liquid biopsies could be used to inform real-time 
clinical decision thus further improving the outcome for MM patients.
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